Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
Historique:
received: 08 10 2020
revised: 17 12 2020
accepted: 29 12 2020
pubmed: 31 12 2020
medline: 25 8 2021
entrez: 30 12 2020
Statut: ppublish

Résumé

Coagulation factor V (FV) plays an anticoagulant role but serves as a procoagulant cofactor in the prothrombinase complex once activated to FVa. At the heart of these opposing effects is the proteolytic removal of its central B-domain, including conserved functional landmarks (basic region, BR; 963-1008 and acidic region 2, AR2; 1493-1537) that enforce the inactive FV procofactor state. Tissue factor pathway inhibitor α (TFPIα) has been associated with FV as well as FV-short, a physiologically relevant isoform with a shortened B-domain missing the BR. However, it is unclear which forms of FV are physiologic ligands for TFPIα. Here, we characterize the binding and regulation of FV and FV-short by TFPIα via its positively charged C-terminus (TFPIα-BR) and examine how bond cleavage in the B-domain influences these interactions. We show that FV-short is constitutively active and functions in prothrombinase like FVa. Unlike FVa, FV-short binds with high affinity (K

Identifiants

pubmed: 33376137
pii: S0021-9258(20)00349-X
doi: 10.1074/jbc.RA120.016341
pmc: PMC7948760
pii:
doi:

Substances chimiques

Ligands 0
Lipoproteins 0
lipoprotein-associated coagulation inhibitor 0
prothrombinase complex 0
Factor Va 65522-14-7
Factor V 9001-24-5
Thromboplastin 9035-58-9
Thrombin EC 3.4.21.5
Factor Xa EC 3.4.21.6

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

100234

Subventions

Organisme : NHLBI NIH HHS
ID : P01 HL139420
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL131833
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007971
Pays : United States

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest R Camire is a consultant for and receives research support from Pfizer and Bayer.

Références

J Biol Chem. 2007 May 18;282(20):15033-9
pubmed: 17387173
Biochim Biophys Acta. 1983 Feb 15;742(3):558-64
pubmed: 6838889
J Thromb Haemost. 2017 Jan;15(1):140-149
pubmed: 27801970
Thromb Haemost. 2016 Mar;115(3):580-90
pubmed: 26607136
Blood. 2011 Jan 6;117(1):290-8
pubmed: 20864578
Biochemistry. 1990 Jul 24;29(29):6762-8
pubmed: 2397212
J Biol Chem. 1998 Apr 24;273(17):10709-18
pubmed: 9553135
Blood. 1982 Jul;60(1):59-63
pubmed: 7082847
Blood. 2008 Nov 1;112(9):3615-23
pubmed: 18695002
Biochemistry. 1997 Oct 7;36(40):12080-6
pubmed: 9315846
Blood. 2001 Mar 15;97(6):1549-54
pubmed: 11238089
Thromb Res. 2012 May;129 Suppl 2:S21-2
pubmed: 22425319
J Biol Chem. 2017 Jun 2;292(22):9335-9344
pubmed: 28420729
Blood. 2014 May 8;123(19):2934-43
pubmed: 24620349
J Thromb Haemost. 2015 Jun;13 Suppl 1:S200-7
pubmed: 26149025
J Biol Chem. 1983 May 25;258(10):6503-8
pubmed: 6406482
Blood. 1996 Mar 1;87(5):1845-50
pubmed: 8634431
Int J Hematol. 2020 Jan;111(1):42-50
pubmed: 30302740
Proc Natl Acad Sci U S A. 1981 Jan;78(1):162-6
pubmed: 6941242
J Thromb Haemost. 2009 Dec;7(12):1951-61
pubmed: 19765210
Biochemistry. 1998 Aug 25;37(34):11896-906
pubmed: 9718313
J Biol Chem. 2004 May 14;279(20):21643-50
pubmed: 15004010
J Clin Invest. 2013 Sep;123(9):3777-87
pubmed: 23979162
J Biol Chem. 1996 Jul 5;271(27):16126-34
pubmed: 8663201
Eur J Biochem. 1997 Jul 1;247(1):12-20
pubmed: 9249003
Front Biosci (Landmark Ed). 2012 Jan 01;17:262-80
pubmed: 22201743
Curr Opin Hematol. 2011 Sep;18(5):338-42
pubmed: 21730834
Pathophysiol Haemost Thromb. 2003;33(1):4-15
pubmed: 12853707
J Biol Chem. 2010 Feb 19;285(8):5212-23
pubmed: 20022942
Biochemistry. 1995 Mar 28;34(12):4118-24
pubmed: 7696276
J Thromb Haemost. 2017 Jul;15(7):1241-1250
pubmed: 28671348
Res Pract Thromb Haemost. 2017 Dec 20;2(1):114-124
pubmed: 30046712
J Biol Chem. 2013 Oct 18;288(42):30151-30160
pubmed: 24014022
J Biol Chem. 1993 Feb 25;268(6):3993-4000
pubmed: 8440691
Blood. 2003 Jan 1;101(1):20-30
pubmed: 12393635
Proc Natl Acad Sci U S A. 1987 Jul;84(14):4846-50
pubmed: 3110773
J Biol Chem. 2019 Feb 15;294(7):2422-2435
pubmed: 30578302
J Vis Exp. 2014 Nov 20;(93):e52099
pubmed: 25490604
Annu Rev Biochem. 1988;57:915-56
pubmed: 3052293
J Biol Chem. 1979 Feb 10;254(3):964-73
pubmed: 762106
J Biol Chem. 1984 Mar 10;259(5):3187-96
pubmed: 6421819
Methods Enzymol. 1993;222:224-36
pubmed: 8412796
Haemophilia. 2016 Jul;22 Suppl 5:3-8
pubmed: 27405668
J Biol Chem. 2012 Jul 27;287(31):26342-51
pubmed: 22707727
J Biol Chem. 2002 Jul 19;277(29):26689-98
pubmed: 12011050
Int J Lab Hematol. 2016 May;38 Suppl 1:4-11
pubmed: 27161771
Blood. 1990 Jul 1;76(1):1-16
pubmed: 2194585
Methods Enzymol. 1976;45:156-76
pubmed: 1011989
J Thromb Haemost. 2012 Sep;10(9):1944-6
pubmed: 22738072
J Biol Chem. 2013 Sep 27;288(39):27789-800
pubmed: 23940050
Blood. 2015 Mar 12;125(11):1822-5
pubmed: 25634741
J Biol Chem. 1993 Dec 25;268(36):26950-5
pubmed: 8262929
Blood. 1988 Dec;72(6):2020-5
pubmed: 3143429
J Biol Chem. 1990 Mar 5;265(7):3708-18
pubmed: 2303476
Biophys J. 2006 Nov 1;91(9):3170-81
pubmed: 16891373
J Biol Chem. 1979 Feb 25;254(4):1326-34
pubmed: 762131
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17838-43
pubmed: 24127605
J Thromb Haemost. 2019 Apr;17(4):585-595
pubmed: 30740865
Semin Thromb Hemost. 2013 Sep;39(6):607-12
pubmed: 23893775
Front Biosci (Schol Ed). 2011 Jun 01;3:1457-62
pubmed: 21622281
J Biol Chem. 1990 Oct 5;265(28):17132-40
pubmed: 2211616
Blood Adv. 2017 Dec 26;1(27):2692-2702
pubmed: 29291252
J Biol Chem. 1982 Jun 10;257(11):6556-64
pubmed: 7076681
J Biol Chem. 2002 Oct 4;277(40):37863-70
pubmed: 12149252

Auteurs

Teodolinda Petrillo (T)

Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Francis Ayombil (F)

Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Cornelis Van't Veer (C)

Center of Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Rodney M Camire (RM)

Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: rcamire@pennmedicine.upenn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH